Drugs / JNJ-64264681
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06788509 | Dec 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, castration-resistant prostate carcinoma, myelodysplastic syndrome | Janssen Research & Development, LLC | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT04657224 | Feb 2021 → Jan 2025 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04210219 | Jul 2020 → May 2025 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03607513 | Jul 2018 → Aug 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64264681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03607513 ↗ |
| Action | Inhibit | “JNJ-64264681 and JNJ-67856633 inhibit BTK and MALT1, respectively, and both BTK and MALT1 are involved in transmitting the pro-survival BCR signal.” NCT04657224 ↗ |
| Modality | Small molecule | — CHEMBL5314920 ↗ |
| Route | Oral | “JNJ-64264681 will be provided as capsules for oral administration.” NCT03607513 ↗ |
| Target | BTK | “JNJ-64264681 and JNJ-67856633 inhibit BTK and MALT1, respectively, and both BTK and MALT1 are involved in transmitting the pro-survival BCR signal.” NCT04657224 ↗ |